Roche and Dualitas enter bispecific discovery collaboration worth more than $1bn
Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.
Roche will pay Dualitas $36.5 million upfront to screen more than 300,000 bispecific antibody combinations using Dualitas' discovery platform against selected therapeutic targets.
The collaboration combines Roche's development capabilities with high-throughput bispecific screening and gives Dualitas potential milestone and commercial payments exceeding $1 billion.
Field | Content |
Alert Type | Deal |
Companies | Roche; Dualitas Therapeutics |
Deal Type | Discovery and licensing collaboration |
Asset or Company | Bispecific antibody discovery platform |
Therapy Area(s) | Immunology; inflammation |
Technology or Modality | Bispecific antibodies; high-throughput antibody screening |
Deal Value | US$36.5 million upfront with total potential economics exceeding US$1 billion |
Screening Scale | More than 300,000 bispecific combinations |
Geography | Global |
What Happened | Roche entered a discovery collaboration with Dualitas to identify bispecific antibody candidates for selected immunology and inflammation targets. |
Why It Matters | The agreement applies high-throughput screening to a very large bispecific design space, potentially accelerating identification of differentiated therapeutic combinations. |
Supporting Context | Dualitas' platform is designed to generate and screen large libraries of bispecific antibodies to identify combinations with desirable biological activity and drug properties. |
Strategic Rationale | Roche gains access to a scalable bispecific discovery engine while Dualitas receives upfront funding and substantial milestone-based economics. |
Potential Impact | Successful programmes could generate new biologic therapies for inflammatory and immune-mediated diseases. |
Key Takeaway | Roche is paying US$36.5 million upfront in a bispecific discovery collaboration with Dualitas carrying more than US$1 billion in potential total value. |
What to Watch | Selection of development candidates, advancement into preclinical studies and disclosure of specific disease targets. |
Primary Source | Fierce Biotech |
Relevant Date | 17 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Kommentare